Free Trial

CorMedix Q1 2023 Earnings Report

CorMedix logo
$9.67 -0.18 (-1.83%)
(As of 01:50 PM ET)

CorMedix EPS Results

Actual EPS
-$0.24
Consensus EPS
-$0.20
Beat/Miss
Missed by -$0.04
One Year Ago EPS
N/A

CorMedix Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

CorMedix Announcement Details

Quarter
Q1 2023
Time
N/A
The 2024 TECH RESET (Ad)

Are we on the edge of the biggest ‘TECH RESET’ in decades?

Click here for the step-by-step details

CorMedix Earnings Headlines

CorMedix supports CMS policy updates
The 2024 TECH RESET
Are we on the edge of the biggest ‘TECH RESET’ in decades?
See More CorMedix Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like CorMedix? Sign up for Earnings360's daily newsletter to receive timely earnings updates on CorMedix and other key companies, straight to your email.

About CorMedix

CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.

View CorMedix Profile

More Earnings Resources from MarketBeat